His main research concerns Leukemia, Immunology, Cancer research, Myeloid and Myeloid leukemia. His study in Leukemia is interdisciplinary in nature, drawing from both Apoptosis, Cytopenia and T cell. His Immunology study frequently links to other fields, such as Internal medicine.
His Cancer research research includes themes of Haematopoiesis and Signal transduction. His studies in Myeloid integrate themes in fields like Molecular biology, Disease, Cell growth and Chromosomal translocation. His Myeloid leukemia research is multidisciplinary, relying on both Fms-Like Tyrosine Kinase 3, Regulation of gene expression, Gene, Gene isoform and Cell biology.
Immunology, Cancer research, Leukemia, Myeloid leukemia and Internal medicine are his primary areas of study. His research in Immunology intersects with topics in Stem cell and Transplantation. His Cancer research study incorporates themes from Apoptosis, Protein kinase B, Signal transduction and Gene expression.
His work deals with themes such as Myeloid, Molecular biology, Haematopoiesis and Cytokine secretion, which intersect with Leukemia. His Myeloid leukemia research integrates issues from Cell, PI3K/AKT/mTOR pathway, Retinoic acid and Pharmacology. His Internal medicine research includes elements of Gastroenterology, Endocrinology and Oncology.
His primary scientific interests are in Myeloid leukemia, Cancer research, Immunology, Stem cell and Internal medicine. The study incorporates disciplines such as Cytokine, Myeloid, Bone marrow, PI3K/AKT/mTOR pathway and Retinoic acid in addition to Myeloid leukemia. His biological study spans a wide range of topics, including Protein kinase B, Tyrosine kinase, Downregulation and upregulation, Leukemia and Kinase.
Øystein Bruserud has included themes like Lonidamine, Signal transduction and Disease in his Leukemia study. His Immunology study frequently involves adjacent topics like Haematopoiesis. His Hematology study in the realm of Internal medicine interacts with subjects such as In patient.
The scientist’s investigation covers issues in Myeloid leukemia, Cancer research, Immunology, Cytokine and PI3K/AKT/mTOR pathway. The concepts of his Myeloid leukemia study are interwoven with issues in Myeloid, Tyrosine kinase, Proteome and Bone marrow. The Cancer research study combines topics in areas such as Cell, Cellular differentiation, Receptor, Syk and Leukemia.
Øystein Bruserud interconnects Chronic fatigue and Stem cell in the investigation of issues within Immunology. His Stem cell study incorporates themes from Transplantation and Minimal residual disease. His work carried out in the field of Cytokine brings together such families of science as Tumor necrosis factor alpha, Sepsis, Chemokine, Intracellular and Allergy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Jonathan M Irish;Randi Hovland;Peter O Krutzik;Omar D Perez.
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li;Tereza Osdal;Yinwei Ho;Sookhee Chun.
Cell Stem Cell (2014)
Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
O. Bruserud;C. Stapnes;E. Ersvær;B. T. Gjertsen.
Current Pharmaceutical Biotechnology (2007)
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life
Jan Samuelsson;Hans Hasselbalch;Oystein Bruserud;Snezana Temerinac.
Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities
Øystein Bruserud;Randi Hovland;Line Wergeland;Tien-Sheng Huang.
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Camilla Stapnes;Anne P. Døskeland;Kimberley Hatfield;Elisabeth Ersvær.
British Journal of Haematology (2007)
Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells.
Jenny Foss Abrahamsen;Anne M. Bakken;Øystein Bruserud.
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Øystein Bruserud;Anita Ryningen;Astrid Marta Olsnes;Laila Stordrange.
Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
Håkon Reikvam;Kimberley Joanne Hatfield;Astrid Olsnes Kittang;Astrid Olsnes Kittang;Randi Hovland.
BioMed Research International (2011)
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Hanne Kristin Fredly;Bjørn Tore Gjertsen;Bjørn Tore Gjertsen;Øystein Bruserud;Øystein Bruserud.
Clinical Epigenetics (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: